The global mammalian cell fermentation technology market size accounted for USD 50.62 billion in 2024, grew to USD 55.13 billion in 2025 and is projected to surpass around USD 118.95 billion by 2034, representing a healthy CAGR of 8.92% between 2024 and 2034. The North America mammalian cell fermentation technology market size is calculated at USD 19.74 billion in 2024 and is expected to grow at a fastest CAGR of 9.06% during the forecast year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Mammalian Cell Fermentation Technology Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Mammalian Cell Fermentation Technology Market, by Type, 2024-2034
8.1.1. Chinese Hamster Ovary (CHO) Cell Fermentation
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Human Embryonic Kidney (HEK) Cell Fermentation
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Baby Hamster Kidney (BHK) Cell Fermentation
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Murine Myeloma Cell Fermentation
8.1.4.1. Market Revenue and Forecast (2021-2034)
9.1. Mammalian Cell Fermentation Technology Market, by Application, 2024-2034
9.1.1. Monoclonal Antibodies
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Recombinant Proteins
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Vaccines
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Hormones
9.1.4.1. Market Revenue and Forecast (2021-2034)
9.1.5. Enzymes
9.1.5.1. Market Revenue and Forecast (2021-2034)
10.1. North America
10.1.1. Market Revenue and Forecast, by Type (2021-2034)
10.1.2. Market Revenue and Forecast, by Application (2021-2034)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Type (2021-2034)
10.1.3.2. Market Revenue and Forecast, by Application (2021-2034)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Type (2021-2034)
10.1.4.2. Market Revenue and Forecast, by Application (2021-2034)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Type (2021-2034)
10.2.2. Market Revenue and Forecast, by Application (2021-2034)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Type (2021-2034)
10.2.3.2. Market Revenue and Forecast, by Application (2021-2034)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Type (2021-2034)
10.2.4.2. Market Revenue and Forecast, by Application (2021-2034)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Type (2021-2034)
10.2.5.2. Market Revenue and Forecast, by Application (2021-2034)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Type (2021-2034)
10.2.6.2. Market Revenue and Forecast, by Application (2021-2034)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Type (2021-2034)
10.3.2. Market Revenue and Forecast, by Application (2021-2034)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Type (2021-2034)
10.3.3.2. Market Revenue and Forecast, by Application (2021-2034)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Type (2021-2034)
10.3.4.2. Market Revenue and Forecast, by Application (2021-2034)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Type (2021-2034)
10.3.5.2. Market Revenue and Forecast, by Application (2021-2034)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Type (2021-2034)
10.3.6.2. Market Revenue and Forecast, by Application (2021-2034)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Type (2021-2034)
10.4.2. Market Revenue and Forecast, by Application (2021-2034)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Type (2021-2034)
10.4.3.2. Market Revenue and Forecast, by Application (2021-2034)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Type (2021-2034)
10.4.4.2. Market Revenue and Forecast, by Application (2021-2034)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Type (2021-2034)
10.4.5.2. Market Revenue and Forecast, by Application (2021-2034)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Type (2021-2034)
10.4.6.2. Market Revenue and Forecast, by Application (2021-2034)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Type (2021-2034)
10.5.2. Market Revenue and Forecast, by Application (2021-2034)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Type (2021-2034)
10.5.3.2. Market Revenue and Forecast, by Application (2021-2034)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Type (2021-2034)
10.5.4.2. Market Revenue and Forecast, by Application (2021-2034)
11.1. Thermo Fisher Scientific, Inc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Merck KGaA
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Danaher
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Lonza
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. F. Hoffmann-La Roche Ltd
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Sartorius AG
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. AstraZeneca
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Bristol-Myers Squibb
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Amgen
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Gilead Sciences
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample